Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Opioids and Related Medications

  • Chapter
  • First Online:
Urological and Gynaecological Chronic Pelvic Pain

  • 990 Accesses

Abstract

Specialty physicians and collaborating providers sometimes place themselves in awkward patient situations when prescribing opioids. Rather than performing risk assessments and monitoring individual patients, standardized prescriptions for procedures or symptom flares are thought to be sufficient to mitigate risk. A keen understanding of the issues surrounding opioid therapy will aid the specialty provider to recognize risk in the treatment of severe pain unresponsive to standard protocols yet respond appropriately and compassionately to legitimate pain complaints.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. CDC. Common elements in guidelines for prescribing opioids for chronic pain. [Online]. http://www.cdc.gov/homeandrecreationalsafety/pdf/Common_Elements_in_Guidelines_for_Prescribing_Opioids-a.pdf. Accessed 12 Jun 2015.

  2. Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. American Pain Society & American Academy of Pain Medicine Opioids guideline panel. Pain. 2009;10(2):113–30.

    Article  CAS  Google Scholar 

  3. VA/DoD. Clinical practice guideline for management of opioid therapy for chronic pain. 2010. [Online]. http://www.va.gov/painmanagement/docs/cpg_opioidtherapy_fulltext.pdf. Accessed 14 Jun 2015.

  4. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2-guidance. Pain Physician. 2012;15:S67–116.

    PubMed  Google Scholar 

  5. Nuckols T, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47.

    Article  PubMed  Google Scholar 

  6. American Geriatric Society. Pharmacologic management of persistent pain in older persons. JAGS. 2009;57(8):1333–46.

    Google Scholar 

  7. Hooten W, Timming R, Belgrade M et al. Institute for Clinical Systems Improvement. Assessment and management of chronic pain. 2013. [Online]. https://www.icsi.org/_asset/bw798b/chronicpain.pdf. Accessed 14 Jun 2015.

  8. Webster L, Webster R. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–42.

    Article  PubMed  Google Scholar 

  9. Akbik H, Butler S, Budman S, et al. Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP). J Pain Symptom Manage. 2006;32(3):287–93.

    Article  PubMed  Google Scholar 

  10. Butler S, Budman S, Fernandez K, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–56.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Belgrade M, Schamber C, Lindgren B. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. Pain. 2006;7(9):671–81.

    Article  Google Scholar 

  12. Passik S, Kirsh K, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26(4):552–61.

    Article  CAS  PubMed  Google Scholar 

  13. Wu S, Compton P, Bolus R, et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage. 2006;32(4):342–51.

    Article  PubMed  Google Scholar 

  14. Jones T, Moore T. Preliminary data on a new opioid risk assessment measure: the brief risk interview. J Opioid Manag. 2013;9(1):19–27.

    Article  PubMed  Google Scholar 

  15. Drugs@FDA. Methadone (Dolophine®). [Package Insert]. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed 14 Jun 2015.

  16. Miller M, Barber C, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA. 2015;175(4):608–15.

    Google Scholar 

  17. Furlan A, Sandoval J, Mailis-Gagnon A, Tunks E. Opioids for chronic non-cancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–94.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Thomsen A, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. Acta Anaesthesiol Scand. 2003;43(9):918–23.

    Article  Google Scholar 

  19. Surratt H, Kurtz S, Cicero T, Dart R. Street prices of prescription opioids diverted to the illicit market. Researched abuse, diversion and addiction-related surveillance (RADARS) system. [Online]. http://www.arsh.nova.edu/presentations/forms/street_prices_of_prescription_opioids_diverted_to_the_illicit_market.pdf. Accessed 13 Jun 2015.

  20. Vranken J. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2009;9(1):71–8.

    Article  CAS  PubMed  Google Scholar 

  21. Zorn KE, Fudin J. Treatment of neuropathic pain: the role of unique opioid agents. Pract Pain Manag. 2011;11(4):26–33.

    Google Scholar 

  22. Finnerup N, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet. 2015;14(2):162–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Attal N, Cruccu G, Hannpaa N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–69.

    Article  CAS  PubMed  Google Scholar 

  24. Jones C, Mack K, Paulozzi L. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.

    Article  CAS  PubMed  Google Scholar 

  25. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307:1934–40.

    Article  CAS  PubMed  Google Scholar 

  26. Substance Abuse and Mental Health Administration. Office of Applied Studies, results from the 2010 National survey on drug use and health: summary of national findings, NSDUH series H-41, HHS Publication No. (SMA) 11–4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.

    Google Scholar 

  27. Kraft WK, Gibson E, Dysart K. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008;122(3):e601–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Katz N, Mazer N. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.

    Article  PubMed  Google Scholar 

  29. Colameco S, Coren J. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009;109(1):20–5.

    PubMed  Google Scholar 

  30. Daniell H. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of non-malignant pain. J Pain. 2008;9(1):28–36.

    Article  CAS  PubMed  Google Scholar 

  31. Ragni G, De Lauretis L, Bestetti O, Sghedoni D, Gambaro V. Gonadal function in male heroin and methadone addicts. Int J Androl. 1988;11(2):93–100.

    Article  CAS  PubMed  Google Scholar 

  32. Brennan M. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3):S12–8.

    Article  CAS  PubMed  Google Scholar 

  33. Palm S, Moenig H, Maier C. Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis. Methods Find Exp Clin Pharmacol. 1997;19(4):269–73.

    CAS  PubMed  Google Scholar 

  34. Allolio B, Schulte H, Deuss U, et al. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol. 1987;114:509–14.

    CAS  PubMed  Google Scholar 

  35. Daniell H. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7(12):901–7.

    Article  CAS  PubMed  Google Scholar 

  36. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85(6):2215–22.

    Article  CAS  PubMed  Google Scholar 

  37. Mulligan T, Frick M, Zuraw Q, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rajagopal A, Vassilopoulou-Sellin R, Palmer J, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100(4):851–8.

    Article  CAS  PubMed  Google Scholar 

  39. Pasternak G. Opioids and their receptors: are we there yet? Neuropharmacology. 2014;76:198–203.

    Article  CAS  PubMed  Google Scholar 

  40. Atkinson T, Fudin J. Interactions between pain medications and illicit street drugs. Pract Pain Manag. 2014;14(7):50–62.

    Google Scholar 

  41. Atkinson T, Fudin J, Wegrzyn E, Bettinger J. Dialysis, opioids, and pain management: where’s the evidence? Pract Pain Manag. 2014;14(8):49–57.

    Google Scholar 

  42. Drugs@FDA. Morphine (MS Contin®). [Package Insert]. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 14 Jun 2015.

  43. D’Honneur G, Gilton A, Sandouk A, Scherrman J, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology. 1994;81(1):87–93.

    Article  PubMed  Google Scholar 

  44. Bartholow M. Top 200 Drugs of 2011. Pharmacy Times. [Online]. 2012. https://s3.amazonaws.com/pharmacytimes/d_media/_pdf/Top_200_Drugs_2011_Total_Rx.pdf. Accessed 14 Jun 2015.

  45. Atkinson T, Fudin J, Pandula A, Mirza M. Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther. 2013;35:1669–89.

    Article  PubMed  Google Scholar 

  46. DEA. Rescheduling of hydrocodone combination products from schedule III to schedule II. [Docket no. – DEA389]. [Online]. http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0822.htm. Accessed 13 Jun 2015.

  47. Drugs@FDA. Hydrocodone ER (Hysingla®). [Package Insert]. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 14 Jun 2015.

  48. Chamberlin K, Cottle M, Neville R, Tan J. Oral oxymorphone for pain management. Ann Pharmacother. 2007;41:1144–52.

    Article  CAS  PubMed  Google Scholar 

  49. Drugs@FDA. Hydromorphone (Exalgo®). [Package Insert]. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 14 June 2015.

  50. Brecht K, Gilaldi H, Hebert T, et al. Intradialytic clearance of opioids: methadone versus hydromorphone. Pain. 2013;154(12):2794–800.

    Article  PubMed  Google Scholar 

  51. Babul N, Darke A, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10(3):184–6.

    Article  CAS  PubMed  Google Scholar 

  52. Larochelle M, Zhang F, Ross-Degnan D, Wharam J. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175(6):978–87.

    Article  PubMed  Google Scholar 

  53. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461–79.

    Article  CAS  PubMed  Google Scholar 

  54. Heiskanen T, Olkkola K, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64:603–11.

    Article  CAS  PubMed  Google Scholar 

  55. Linares O, Daly D, Linares A, Setefanovski D, Boston R. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med. 2014;15:791–806.

    Article  PubMed  Google Scholar 

  56. Drugs@FDA. Oxymorphone (Opana®). [Package Insert]. 2006. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed 14 Jun 2015.

  57. Portenoy R, Southam M, Gupta S, et al. Transdermal fentanyl for cancer pain. Anesthesiology. 1993;78(1):36–43.

    Article  CAS  PubMed  Google Scholar 

  58. Drugs@FDA. Fentanyl (Duragesic®). [Package Insert]. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 14 June 2015.

  59. Zhou S. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part I. Clin Pharmacokinet. 2009;48(11):689–723.

    Article  CAS  PubMed  Google Scholar 

  60. Zhou S. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part II. Clin Pharmacokinet. 2009;48(12):761–804.

    Article  CAS  PubMed  Google Scholar 

  61. Ashburn M, Odgden L, Ahang J, et al. The pharmacokinetics of transdermal fentanyl delivered with and without heat. Pain. 2003;4(6):291–7.

    Article  CAS  Google Scholar 

  62. Budd K. Old dog–new (ma)trix. Br J Anaesth. 2003;90:2–4.

    Article  Google Scholar 

  63. Likar R. Transdermal buprenorphine in the management of persistent pain- safety aspects. Ther Clin Risk Manag. 2006;2(1):115–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Booth M. Opium: a history. London: Simon & Schuster; 1996.

    Google Scholar 

  65. Bullingham R, McQuay J, Moore A, et al. Buprenorphine Kinetics. Clin Pharmacol Ther. 1980;28:667–72.

    Article  CAS  PubMed  Google Scholar 

  66. Dahan A, Yassen A, Bijl H, et al. A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans rats. Br J Anaesth. 2005;94:825–34.

    Article  CAS  PubMed  Google Scholar 

  67. Boas R, Villiger J. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth. 1985;57:192–6.

    Article  CAS  PubMed  Google Scholar 

  68. Kapil R, Cipriano A, Friedman K, et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manage. 2013;46(1):65–75.

    Article  PubMed  Google Scholar 

  69. Greenwald M, Johanson C, Moody D, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28:2000–9.

    Article  CAS  PubMed  Google Scholar 

  70. Jasinski D, Pevnick J, Griffith J. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry. 1978;35:501–16.

    Article  CAS  PubMed  Google Scholar 

  71. Evans H, Easthope S. Transdermal buprenorphine. Drugs. 2003;63(19):1999–2010.

    Article  CAS  PubMed  Google Scholar 

  72. Stringer M, Makin M, Miles J, et al. d-morphine, but not l-morphine, has low micromolar affinity for the non-competitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neurosci Lett. 2000;295:21–4.

    Article  CAS  PubMed  Google Scholar 

  73. Codd E, Shank R, Schupsky J, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70.

    CAS  PubMed  Google Scholar 

  74. Fudin J. Opioid pain management: Balancing risks and benefits. CE program of the University of Connecticut School of Pharmacy and Drug Topics. Drug Topics. 2011;2011:46–58.

    Google Scholar 

  75. Wang Y, Li J, Huang P, et al. Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, densensitization, internalization, and down regulation. J Pharmacol Exp Ther. 2003;307(3):1127–34.

    Article  CAS  PubMed  Google Scholar 

  76. Yamamura T, Harada K, Okamura A, et al. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology. 1990;72:704–10.

    Article  CAS  PubMed  Google Scholar 

  77. Clark J, Kalan G. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 1995;10(4):310–4.

    Article  CAS  PubMed  Google Scholar 

  78. Qiu S, Chen T, Koga K, et al. An increase in synaptic NMDA receptors in the insular cortex contributes to neuropathic pain. Sci Signal. 2013;6(275):1–11.

    Article  Google Scholar 

  79. Ho Y, Cheng J, Chiou L. Hypofunction of glutamatergic transmission in the periaqueductal gray contributes to nerve-injury induced neuropathic pain. Neuroscience. 2013;33(18):7825–36.

    Article  CAS  PubMed  Google Scholar 

  80. Trujillo K, Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res. 1994;633(1–2):178–88.

    Article  CAS  PubMed  Google Scholar 

  81. Fudin J, Marcoux M, Fudin J. A mathematical model for methadone conversion examined. Pract Pain Manag. 2012;2012:46–51.

    Google Scholar 

  82. Prommer E. Levorphanol: the forgotten opioid. Support Care Cancer. 2007;15:259–64.

    Article  PubMed  Google Scholar 

  83. Drugs@FDA. Levorphanol (Levo-Dromoran®). [Package Insert]. 2000. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 14 Jun 2015.

  84. Morbidity and mortality weekly report. Vital signs: risk for overdose from methadone used for pain relief – United States, 1999–2010. 2012. Centers for Disease Control and Prevention. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm?s_cid=mm6126a5_w. Accessed 15 Jun 2015.

  85. Centers for Disease Control and Prevention. CDC features: prescription painkiller overdoses: methadone.2012. Centers for Disease Control and Prevention. http://www.cdc.gov/features/vitalsigns/methadoneoverdoses/. Accessed 15 Jun 2015.

  86. Rowbotham M, Twilling L, Davies P, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. NEJM. 2003;348:1223–32.

    Article  CAS  PubMed  Google Scholar 

  87. Tzschentke T, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265–76.

    Article  CAS  PubMed  Google Scholar 

  88. Carter G, Sullivan M. Antidepressants in pain management. Curr Opin Investig Drugs. 2002;3:454–8.

    CAS  PubMed  Google Scholar 

  89. Max M, Lynch S, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Eng J Med. 1992;326:1250–6.

    Article  CAS  Google Scholar 

  90. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol. 2004;19:S21–5.

    Article  CAS  PubMed  Google Scholar 

  91. Malseed R, Goldstein F. Enhancement of morphine analgesia by tricyclic antidepressants. Neuropharmacology. 1979;18:827–9.

    Article  CAS  PubMed  Google Scholar 

  92. Botney M, Fields H. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13:160–4.

    Article  CAS  PubMed  Google Scholar 

  93. Drugs@FDA. Nucynta ER® (Tapentadol HCl). [Package Insert]. 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed 15 Jun 2015.

  94. Raffa R, Friderichs E, Reimann W, et al. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260:275–85.

    CAS  PubMed  Google Scholar 

  95. Raffa R, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between enantiomers of tramadol. J Pharmacol Exp Ther. 1993;267(1):331–40.

    CAS  PubMed  Google Scholar 

  96. Frink M, Hennies H, Englberger W, et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996;46(11):1029–36.

    CAS  PubMed  Google Scholar 

  97. Boyer E, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112–20.

    Article  CAS  PubMed  Google Scholar 

  98. Drugs@FDA. Ultram® (Tramadol HCl). [Package Insert]. 2009. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 15 Jun 2015.

  99. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996;60:636–44.

    Article  CAS  PubMed  Google Scholar 

  100. Hartrick C, Hove I, Stegmann J, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10 day, phase iii, randomized, double-blind active- and placebo-controlled study. Clin Ther. 2009;31(2):260–71.

    Article  CAS  PubMed  Google Scholar 

  101. Pizzi L, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32(6):502–14.

    Article  CAS  PubMed  Google Scholar 

  102. Jonas D, Wines R. Pharmacogenomic testing and the prospect of individualized treatment. N C Med J. 2013;74(6):485–93.

    PubMed  Google Scholar 

  103. Polk B, Becker M. Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. Discov Med. 2013;16(90):267–75.

    PubMed  Google Scholar 

  104. Liu X, Cheng D, Kuang Q, et al. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One. 2013;8(3), e58489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Chen J, Zhao Q, Shi G, Wang L. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B. 2012;13(11):875–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Gamazon E, Lamba J, Pounds S, et al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013;121(21):4366–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Molto J, Xinarianos G, Miranda C, et al. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet. 2013;52(7):543–53.

    Article  CAS  PubMed  Google Scholar 

  108. Kagan R, Johnson E, Siaw W, et al. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One. 2012;7(9), e46334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Carlyn CJ, Baltch AL, Smith RP, St Clair M, George Mary, Lutz J, Fudin J. HIV genotyping for optimizing therapy. Presented at the infectious disease society of America 38th annual meeting, New Orleans, LA, 7–10 Sept 2000.

    Google Scholar 

  110. Wang W, Wang N, Wang J, Wang Z, Wu R. Delivering systems pharmacogenomics towards precision medicine through mathematics. Adv Drug Deliv Rev. 2013;65(7):905–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Arab-Alameddine M, Decosterd L, Buclin T, Telenti A, Csajka C. Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opin Drug Metab Toxicol. 2011;7(5):609–22.

    Article  CAS  PubMed  Google Scholar 

  112. Fudin J, Atkinson T. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med. 2014;15:723–5.

    Article  PubMed  Google Scholar 

  113. Ciszkowski C, Madadi P, Phillips M, Lauwers A, Koren G. Codeine, ultrarapid metabolism genotype, and postoperative death. N Engl J Med. 2009;361(8):827–8.

    Article  CAS  PubMed  Google Scholar 

  114. Madadi P, Ross C, Hayden M, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clin Pharmacol Ther. 2009;85(1):31–5.

    Article  CAS  PubMed  Google Scholar 

  115. Gan S, Ismail R, Wan Adnan W, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diag Ther. 2007;11(3):171–81.

    Article  CAS  Google Scholar 

  116. Lotsch J, Geisslinger G. A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci. 2010;31(7):312–7.

    Article  PubMed  Google Scholar 

  117. Lacroix-Fralish M, Mogil J. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol. 2009;49:97–121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Reyes-Gibby C, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30.

    Article  CAS  PubMed  Google Scholar 

  119. Lotsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther. 2009;124(2):168–84.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VA Tennessee Valley Healthcare System, Murfreesboro, TN, USA

    Timothy J. Atkinson Pharm. D., B.C.P.S.

  2. Scientific and Clinical Affairs, REMITIGATE LLC, Delmar, NY, USA

    Jeffrey Fudin Pharm.D., F.C.C.P., F.A.S.H.P.

  3. Pharmacy Practice, Western New England University College of Pharmacy, Springfield, MA, USA

    Jeffrey Fudin Pharm.D., F.C.C.P., F.A.S.H.P.

Authors
  1. Timothy J. Atkinson Pharm. D., B.C.P.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Fudin Pharm.D., F.C.C.P., F.A.S.H.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy J. Atkinson Pharm. D., B.C.P.S. .

Editor information

Editors and Affiliations

  1. The Arthur Smith Institute for Urology, Hofstra Northwell School of Medicine, Northwell Health, Lake Success, New York, USA

    Robert M. Moldwin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Atkinson, T.J., Fudin, J. (2017). Opioids and Related Medications. In: Moldwin, R. (eds) Urological and Gynaecological Chronic Pelvic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-48464-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-48464-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-48462-4

  • Online ISBN: 978-3-319-48464-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation